|
Market Closed -
Nasdaq
16:00:00 2026-08-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.7000 USD | +4.14% |
|
-38.05% | -55.70% |
| 08-17 | EyePoint's drug for age-related eye disease fails late-stage trial, shares tank | RE |
| 08-17 | Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 131M | - | - | - | ||
| 48.63B | |||||
| 46.3B | - | - | - | - | - |
| 41.97B | |||||
| 39.51B | |||||
| 31.75B |
Select your edition
All financial news and data tailored to specific country editions
